TY - JOUR
T1 - Tuning Caco-2 permeability by cocrystallization
T2 - Insights from molecular dynamics simulation
AU - Pandey, Noopur
AU - Kumari, Nimmy
AU - Roy, Parag
AU - Mondal, Susanta Kumar
AU - Thakur, Abhishek
AU - Sun, Changquan Calvin
AU - Ghosh, Animesh
N1 - Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2024/1/25
Y1 - 2024/1/25
N2 - Emerging evidence suggests that intestinal permeability can be potentially enhanced through cocrystallization. However, a mechanism for this effect remains to be established. In this study, we first demonstrate the enhancement in intestinal permeability, evaluated by the Caco-2 cell permeability assay, of acetazolamide (ACZ) in the presence of a conformer, p-aminobenzoic acid (PABA), delivered in the form of a 1:1 cocrystal. The binding strength of ACZ and PABA with the Pgp efflux transporter, either alone or as a mixture, was calculated using molecular dynamics simulation. Results show that PABA weakens the binding of ACZ with Pgp, which leads to a lower efflux ratio and elevated permeability of ACZ. This work provides molecular-level insights into a potentially effective strategy to improve the intestinal permeability of drugs. If the same cocrystal also exhibits higher solubility, oral bioavailability of BCS IV drugs can likely be improved by forming a cocrystal with a Pgp inhibitor.
AB - Emerging evidence suggests that intestinal permeability can be potentially enhanced through cocrystallization. However, a mechanism for this effect remains to be established. In this study, we first demonstrate the enhancement in intestinal permeability, evaluated by the Caco-2 cell permeability assay, of acetazolamide (ACZ) in the presence of a conformer, p-aminobenzoic acid (PABA), delivered in the form of a 1:1 cocrystal. The binding strength of ACZ and PABA with the Pgp efflux transporter, either alone or as a mixture, was calculated using molecular dynamics simulation. Results show that PABA weakens the binding of ACZ with Pgp, which leads to a lower efflux ratio and elevated permeability of ACZ. This work provides molecular-level insights into a potentially effective strategy to improve the intestinal permeability of drugs. If the same cocrystal also exhibits higher solubility, oral bioavailability of BCS IV drugs can likely be improved by forming a cocrystal with a Pgp inhibitor.
KW - Acetazolamide
KW - All-atom molecular dynamics
KW - Caco-2 cell
KW - Cocrystallization
KW - Efflux
KW - P-glycoprotein
KW - Permeability
UR - http://www.scopus.com/inward/record.url?scp=85180106612&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85180106612&partnerID=8YFLogxK
M3 - Article
C2 - 38065346
AN - SCOPUS:85180106612
SN - 0378-5173
VL - 650
JO - International journal of pharmaceutics
JF - International journal of pharmaceutics
M1 - 123666
ER -